Puerto Rico hospitals struggling after Hurricane Maria

Some patients in Puerto Rico are having to evacuate to the continental United States for treatment as the island deals with significant damage caused by Hurricane Maria.

As Reuters reported, the challenges faced by Puerto Rico as a whole—the electrical grid is down and there are hours-long lines for gasoline to fuel generators—are heavily impacting hospitals. Some have resorted to protecting fuel shipments to facilities with armed guards to deter potential looters. With some hospitals running low on supplies and many backup generators failing, options for patients are dwindling.

“Another hospital wants to transfer two critical patients here because they don’t have electricity,” said Ivan Gonzalez Cancel, MD, a cardiovascular surgeon and director of the heart transplant program at Centro Cardiovascular. “We can’t take them. We have the same problem.”

Cancel was approached by family members of a patient who has been waiting for a triple-bypass surgery. His advice: Get him off the island.

“Get him on a plane. You can be in Miami in two and a half hours,” he said.

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.